Soleno Therapeutics Inc
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more
Soleno Therapeutics Inc (SLNO) - Total Liabilities
Latest total liabilities as of December 2025: $113.72 Million USD
Based on the latest financial reports, Soleno Therapeutics Inc (SLNO) has total liabilities worth $113.72 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Soleno Therapeutics Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Soleno Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Soleno Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Soleno Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Intershop Holding AG
SW:ISN
|
Switzerland | CHF825.10 Million |
|
Dialog Group Bhd
KLSE:7277
|
Malaysia | RM3.37 Billion |
|
Titan Cement International S.A.
PINK:TTCIF
|
USA | $1.57 Billion |
|
Yamada Holdings Co. Ltd
PINK:YMDAF
|
USA | $774.51 Billion |
|
Werner Enterprises Inc
NASDAQ:WERN
|
USA | $1.50 Billion |
|
Hangzhou Shunwang Tech
SHE:300113
|
China | CN¥459.28 Million |
|
Genmab AS
NASDAQ:GMAB
|
USA | $44.68 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Soleno Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Soleno Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Soleno Therapeutics Inc (2012–2025)
The table below shows the annual total liabilities of Soleno Therapeutics Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $113.72 Million | +32.44% |
| 2024-12-31 | $85.86 Million | +270.34% |
| 2023-12-31 | $23.18 Million | +43.56% |
| 2022-12-31 | $16.15 Million | -9.07% |
| 2021-12-31 | $17.76 Million | -8.62% |
| 2020-12-31 | $19.43 Million | -16.32% |
| 2019-12-31 | $23.23 Million | +82.33% |
| 2018-12-31 | $12.74 Million | +2.01% |
| 2017-12-31 | $12.49 Million | +486.33% |
| 2016-12-31 | $2.13 Million | -57.21% |
| 2015-12-31 | $4.98 Million | -73.42% |
| 2014-12-31 | $18.73 Million | -52.53% |
| 2013-12-31 | $39.45 Million | +7.47% |
| 2012-12-31 | $36.71 Million | -- |